KRAS and Patent ductus arteriosus: The gemcitabineresistance of the PDA cell lines correlated with the amount of CSC features, such asp53 and K-ras status, morphology, self-renewal potential, tumorigenicity, and theexpression of E-cadherin and vimentin (Table S1).